Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dr Reddy’s: Lacking growth drivers - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Oct 28, 2003

    Dr Reddy’s: Lacking growth drivers

    Domestic pharma major, Dr Reddy’s Laboratories (DRL) has announced its 2QFY04 results. On a standalone basis, DRL has reported an 11% increase in topline and a 5% rise in bottomline. While the bulk drugs and formulations business saw modest growth, the generics and diagnostics businesses acted as dampeners. On a consolidated basis, while the group has reported a 13% rise in net sales, net profit has dropped by 15%. In this context, let us undertake a detailed review of the company’s performance during the period.

    Results at a glance (standalone)...
    (Rs m) 2QFY03 2QFY04 Change 1HFY03 1HFY04 Change
    Net Sales 4,037 4,486 11.1% 7,852 9,253 17.8%
    Other Income 167 215 28.1% 334 409 22.5%
    Expenditure 2,934 3,264 11.3% 5,810 6,606 13.7%
    Operating Profit (EBDIT) 1,103 1,222 10.7% 2,042 2,646 29.6%
    Operating Profit Margin (%) 27.3% 27.2%   26.0% 28.6%  
    Interest 13 3 -77.1% 27 6 -78.8%
    Depreciation 144 171 18.8% 281 335 19.4%
    Profit before Tax 1114 1262 13.4% 2068 2714 31.3%
    Tax 122 217 78.7% 274 434 58.2%
    Profit after Tax/(Loss) 992 1045 5.4% 1793 2280 27.1%
    Net profit margin (%) 24.6% 23.3%   22.8% 24.6%  
    No. of Shares 76.5 76.5   76.5 76.5  
    Diluted Earnings per share* 51.9 54.6   46.9 59.6  
    P/E Ratio   20.7     19.0  
    (* annualised)            

    DRL’s topline growth was fuelled by a strong rise in bulk drug sales. The European and domestic markets were the key growth drivers in this business. In the European markets, launch of ‘Ramipril’ contributed Rs 380 m to the revenues. In the domestic market, increase in volumes of key products led the growth. However, bulk drug revenues from the North American market saw a sharp decline due to poor showing by ‘Nizatidine’.

    In the formulations business, DRL saw a modest 6% growth. Although DRL showed strong performance in the domestic market due to the company’s strategy of focusing on key brands, the growth was offset by the decline in the revenues from ‘Ciprolet’ and ‘Becelac’ and discontinuance of certain brands due to the rationalisation exercise undertaken by the company. On the basis of therapeutic segments, gastro (20% growth), dental (16%) and cardiovascular (14%) were the top performers. However, naturals (33% drop), specialty (10%) and anti-infectives (3%) saw a drop in revenues. In the international market, formulations sales were affected due to a decline in the revenues from Russia. In Russia, longer custom clearance process resulted in delay in delivery and lower revenues.

    However, the growth in the above business was offset by DRL’s dismal performance in the generics business. Revenues from ‘Tizanidine’ from North America dropped from Rs 337 m in 2QFY03 to Rs 212 m in 2QFY04. Revenues from the critical care and biotechnology segment dropped on account of the closure of diagnostics operations in 1QFY04.

    Revenue mix by segment
    (Rs m) 2QFY03 2QFY04 % change 1HFY03 1HFY04 % change
    Bulk drugs 1,695 2,179 28.5% 3,479 3,859 10.9%
    Formulations 2,001 2,116 5.7% 3,693 3,915 6.0%
    Generics 823 625 -24.0% 1,146 1,732 51.2%
    Diagnostics, Critical Care and
    109 94 -13.3% 205 169 -17.5%
    Drug Discovery - 1 - - 1 -
    Total 4,628 5,016 8.4% 8,523 9,676 13.5%

    On the operations front, although a change in product and market mix helped DRL improve its efficiencies, a rise in legal and R&D expenses resulted in a marginal drop in operating profit margins. R&D expenses increased by 29% to Rs 490 m due to an increase in the number of projects in the areas of Generics and Specialty and higher development activity in APIs. However, higher depreciation and tax provision (due to higher deferred tax) has resulted in DRL recording a meager 5% growth in PAT.

    During 2QFY04, DRL has invested Rs 77 m in Aurigene Discovery Technologies and Aurigene Inc, bringing the total investments to Rs 927 m. The company made a further Rs 18 m investment in its subsidiary in Brazil, Rs 90 m in its subsidiary in Netherlands, Rs 29 m in its joint venture in China and Rs 251 for acquisition of land for future R&D initiatives. DRL also incurred normal capital expenditure of Rs 460 m during 2QFY04.

    At Rs 1130, DRL is trading at a P/E of 21x its annualised 1HFY04. DRL has increased its R&D thrust and is focusing on Para IV ANDA filings. This coupled with the pending approval of Amlodipine Maleate could translate into higher growth in revenus going forward. However, the approval of Amlodipine Maleate is in under litigation and the company does not have any major drug launch in the near term. This is a cause for concern.



    Equitymaster requests your view! Post a comment on "Dr Reddy’s: Lacking growth drivers". Click here!


    More Views on News

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

    Sep 12, 2016

    Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)


    • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts